Who is at risk
- Inherited gene changes — BRCA1 and BRCA2 are the most important, carrying a substantially raised lifetime risk. Lynch syndrome and several other genes (RAD51C/D, BRIP1, PALB2) also contribute. Around 1 in 5 ovarian cancers is linked to an inherited change.
- Family history of ovarian, breast, colorectal or endometrial cancer — on either your mother's or your father's side. Fathers pass on BRCA mutations just as often, and family histories are often taken only on the maternal side.
- Age — risk rises after menopause; most cases occur after 50.
- Never having been pregnant, infertility, early periods or late menopause.
- Endometriosis, which is associated with clear cell and endometrioid subtypes.
- Hormone therapy after menopause (oestrogen-only, long duration), and obesity.
- Protective: combined oral contraceptives (substantially, and the effect lasts decades), pregnancy, breastfeeding, and tubal ligation or removal of the fallopian tubes.
Finding it early
There is no effective screening test for ovarian cancer in women at average risk, and this is one of the most disappointing facts in oncology. CA-125 blood testing and transvaginal ultrasound have been studied in large trials and have not been shown to reduce deaths in the general population; they produce many false alarms and unnecessary operations. Major bodies recommend against routine screening in average-risk women. If someone offers you an ovarian cancer screening blood test, that is the context.
What replaces screening is symptom awareness. The symptoms are genuinely non-specific — that is the problem — but the pattern is not:
- Bloating or increased abdominal size
- Pelvic or abdominal pain
- Feeling full quickly or difficulty eating
- Urinary urgency or frequency
The rule that matters: new, persistent, and frequent. Symptoms that are new (not lifelong), happen most days, and have lasted more than about three weeks deserve evaluation — not another course of treatment for irritable bowel. Ask specifically: "could this be ovarian?" It is a reasonable question and it changes which tests get ordered.
Women at high inherited risk are different. If you carry BRCA1, BRCA2 or another high-risk gene, you will be offered surveillance and, more importantly, risk-reducing removal of the tubes and ovaries after childbearing, which is the only intervention shown to substantially reduce ovarian cancer deaths in this group. If ovarian or breast cancer runs in your family, genetic counselling is the single most valuable appointment on this page.
How it’s diagnosed
Assessment usually starts with pelvic examination, transvaginal ultrasound and a CA-125 blood test — useful once there is a suspicious mass, even though it fails as a screening test. CT of the chest, abdomen and pelvis assesses spread.
Diagnosis is usually confirmed at surgery rather than by needle biopsy, because sampling can spill cells within the abdomen. Where surgery is not the first step, a biopsy may be taken to allow chemotherapy first.
Genetic testing is recommended for every woman diagnosed with ovarian cancer — not only those with a family history. It identifies BRCA and related mutations that determine eligibility for PARP inhibitor therapy, and it has direct implications for relatives. If nobody has offered it, ask.
Most "ovarian" cancers are now understood to arise in the fallopian tube, which is why removing the tubes is increasingly recommended at the time of other pelvic surgery in women who have completed childbearing.
Staging explained simply
Ovarian cancer uses the FIGO system and is staged surgically. Its pattern of spread is distinctive: rather than travelling mainly through blood or lymph, it sheds cells that settle across the lining of the abdomen. This is why surgery aims to remove all visible disease throughout the abdomen, and why the completeness of that surgery is one of the strongest predictors of outcome.
| Stage | What it means in plain words |
|---|---|
| Stage I | Confined to one or both ovaries or fallopian tubes. |
| Stage II | Spread within the pelvis — uterus, tubes, or other pelvic tissue. |
| Stage III | Spread to the abdominal lining outside the pelvis, or to lymph nodes behind the abdomen. Most cases are found here. |
| Stage IV | Spread beyond the abdomen — to the lungs, liver interior, or other distant organs. |
Grading and biology
Ovarian cancer is not one disease. High-grade serous carcinoma is the most common and most aggressive, usually arising in the fallopian tube and usually diagnosed at stage III or IV. Low-grade serous, endometrioid, clear cell and mucinous carcinomas behave differently, respond differently to chemotherapy, and are managed differently.
Separately, germ cell and sex cord-stromal tumours occur in younger women, are often caught early, and are frequently curable with fertility-sparing surgery. If you are young and have been given an ovarian cancer diagnosis, the subtype matters enormously — do not assume the statistics you have read apply.
BRCA and homologous recombination deficiency (HRD) status are the key molecular findings: they predict sensitivity to platinum chemotherapy and eligibility for PARP inhibitors, which have meaningfully extended remissions.
How it’s treated
Surgery is central, and who performs it matters. The goal is complete removal of all visible disease (cytoreduction). Outcomes are measurably better when surgery is done by a gynaecologic oncologist at a centre that does this regularly. This is one of the few situations where asking about your surgeon's specialty and volume is entirely appropriate and genuinely affects survival.
Chemotherapy — usually carboplatin and paclitaxel — is given after surgery, or before surgery (neoadjuvant) when disease is extensive, with surgery in the middle of the course.
PARP inhibitors as maintenance therapy after chemotherapy have substantially extended remission, particularly for BRCA-mutated and HRD-positive cancers. Bevacizumab is added in some situations.
Radiation has only a limited role in ovarian cancer, and we would rather say that clearly than imply otherwise. It is not part of standard curative treatment. It is used selectively — to control a symptomatic site, treat isolated recurrence, relieve bleeding or pain, or occasionally for oligometastatic disease with stereotactic technique. If you are looking for radiation to be the answer here, it usually is not.
Where CureRays fits: honestly, at the margins for this cancer — symptom control and selected isolated sites. Your gynaecologic oncologist and medical oncologist lead. We would rather tell you that than sell you something.
What the guidelines say
In broad strokes: refer suspected ovarian cancer to a gynaecologic oncologist before surgery; aim for complete cytoreduction, using neoadjuvant chemotherapy where upfront complete surgery is not achievable; offer genetic testing to every woman diagnosed; treat with platinum-based chemotherapy; and use PARP inhibitor maintenance guided by BRCA and HRD status. Risk-reducing surgery is recommended for women with high-risk inherited mutations after childbearing.
Your team will follow national guidelines such as those from the National Comprehensive Cancer Network (NCCN). The above is a plain-language overview of the general approach, not the guideline itself. NCCN publishes free NCCN Guidelines for Patients®.
Outcomes and odds of cure
We are not publishing a stage-by-stage survival table on this page, because we could not retrieve current SEER figures at the time of writing — our searches for the ovarian Stat Facts page failed, and we will not fill that gap from memory or from an older dataset presented as current. That is a deliberate choice: on a page someone may read the night they are diagnosed, a wrong number is worse than no number.
For current figures, see NCI SEER Cancer Stat Facts and select ovarian cancer.
What can be said reliably and matters more for you personally: outcome depends heavily on stage, on subtype, and on whether all visible disease was removed at surgery. Early-stage and germ cell tumours often do very well. High-grade serous cancer found at stage III or IV is serious — and PARP inhibitors have genuinely lengthened remissions in recent years, so figures based on women treated a decade ago understate what is achievable now. Ask your gynaecologic oncologist for numbers matched to your stage, subtype, BRCA/HRD status and surgical result.
Population statistics describe large groups, not individuals, and cannot predict what will happen to you.
Side effects and how we watch for them
Surgery is often extensive. Removing both ovaries causes immediate surgical menopause in premenopausal women — hot flushes, sleep and mood changes, and long-term bone and cardiovascular considerations that deserve a proper plan rather than a passing mention.
Carboplatin and paclitaxel: low blood counts, fatigue, hair loss, and peripheral neuropathy — tingling and numbness in hands and feet that can become permanent. Report it as soon as it starts, because dose adjustment early prevents lasting damage. Allergic reactions to carboplatin become more likely with repeated courses.
PARP inhibitors: nausea, fatigue and low blood counts, needing regular blood monitoring.
Bowel obstruction is a recognised complication of advanced disease and needs urgent assessment — vomiting, absolute constipation and a distended abdomen are not symptoms to wait out.
How it is assessed: graded at each visit on a standard scale, with blood counts and CA-125 tracked as a marker of response.
Follow-up, remission and survivorship
Remission means no detectable cancer. Ovarian cancer commonly recurs, and much of long-term care is about managing successive remissions rather than a single cure — this is hard to hear and better said plainly than discovered later.
Follow-up is examination and CA-125 every few months, with imaging as indicated. A rising CA-125 without symptoms does not automatically mean starting treatment — trials have shown that treating on a rising marker alone, before symptoms appear, does not extend life and does shorten time feeling well. This is worth understanding before the number goes up, because the instinct to act immediately is powerful.
Survivorship: menopausal management, bone health, neuropathy, fatigue, sexual health, and the psychological weight of surveillance. If genetic testing found a mutation, make sure relatives are told — cascade testing lets sisters and daughters take preventive action that genuinely saves lives.
Questions people actually ask
Can I be screened for ovarian cancer?
Not effectively, if you are at average risk. CA-125 and ultrasound have been tested in large trials and did not reduce deaths, while causing false alarms and unnecessary surgery. Women with BRCA or other high-risk mutations are managed differently, including risk-reducing surgery.
I'm bloated most days. Should I worry?
If it is new, happens most days, and has lasted more than about three weeks, get it assessed — and say the word 'ovarian' out loud. Most such symptoms are not cancer, but this is precisely the pattern that gets attributed to IBS for months.
Why does everyone say ovarian cancer is silent?
Because its symptoms are ordinary rather than absent. Most women do have symptoms beforehand — bloating, early fullness, pelvic discomfort — but they are easily explained away by both patients and clinicians. 'Whispers' is more accurate than 'silent'.
Does it matter who does my surgery?
Yes, more than in most cancers. Outcomes are measurably better when cytoreductive surgery is performed by a gynaecologic oncologist at a centre that does it regularly. Asking about specialty and volume is reasonable and worth doing.
Should my daughters be tested?
If you carry a BRCA or other high-risk mutation, yes — cascade testing lets relatives access screening and risk-reducing options. Every woman diagnosed with ovarian cancer should be offered genetic testing, regardless of family history.
Will I have radiation?
Probably not. Radiation is not part of standard curative treatment for ovarian cancer. It is used selectively for symptom control or an isolated site of recurrence. Surgery and chemotherapy lead here.
Informational only, not medical advice — confirm with your care team.
Go deeper on ovarian cancer
Read the full plain-language guide, or talk with us if radiation has been suggested for a specific site.